This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
Nintedanib* is an angiokinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) α and ß and fibroblast growth factor receptors (FGFR) 1–3.1 This page details nintedanib’s licensing and MoA.
Nintedanib (VARGATEF®) is approved in the EU and in other countries worldwide in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.1
The role of angiogenesis in cancer
Angiogenesis plays a crucial role in the development of cancer, with tumour growth and metastatic spread dependent on it.2 Angiogenesis is stimulated when tissues or tumour cells require oxygen and nutrients, and is regulated by growth factors that bind to and activate growth factor receptor tyrosine kinases to drive downstream signalling.2-5 Angiokinase inhibitors can block components of the angiogenesis signalling pathway, thus limiting tumour growth.4,6
Nintedanib’s mechanism of action
Nintedanib is a triple angiokinase inhibitor that simultaneously inhibits the kinase activity of vascular endothelial growth factor receptors (VEGFRs) 1–3, platelet-derived growth factor receptors (PDGFRs) α and β, and fibroblast growth factor receptors (FGFRs) 1–3.1,7,8 In doing so, nintedanib blocks the following functions of its target kinases:
Intracellular signalling via these receptors is crucial for the proliferation and survival of endothelial cells and perivascular cells (pericytes and vascular smooth muscle cells).1 Nintedanib competitively binds to the adenosine triphosphate (ATP) binding pocket of these receptors, in the cleft between the NH2- and the COOH-terminal lobes of the kinase domain.8 By binding to these receptors and blocking intracellular signalling, nintedanib hinders the formation of new tumour blood vessels, inhibits vessel maturation and disrupts the maintenance of vascular integrity, which impacts upon tumour growth.6,7,11
Triple angiokinase inhibition and target cells of nintedanib
PDGFR, platelet-derived growth factor receptor; FGFR, fibroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor.
Preclinical studies have shown that nintedanib blocks VEGFR-2 activation for up to 32 hours, providing sustained inhibition of receptor activation.8 Preclinical data also show that nintedanib inhibits Akt and MAPK phosphorylation in endothelial and vascular smooth muscle cells and pericytes. It also induces rapid changes in tumour perfusion and permeability, as measured by DCE-MRI, in xenograft models of different tumour types. The antitumour activity of nintedanib was reported in a number of different tumour xenograft models, including a Calu-6 NSCLC model. In addition, the combination of nintedanib with docetaxel or pemetrexed has also been shown to increase antitumour activity in xenograft models.12
Nintedanib does not induce epithelial-to-mesenchymal transition (EMT) and does not induce an invasive phenotype in vitro;13 indeed, it has been shown to potentially reverse EMT in vitro.14
In addition to NSCLC,15 nintedanib has also been investigated in patients with various solid tumours, including MPM,16 colorectal cancer,17 ovarian cancer,18 hepatocellular carcinoma19 and renal cell carcinoma.20
Nintedanib (VARGATEF®) summary of product characteristics - January 2015. Accessed: July 2017.
de Mello RA, et al. Recent Pat Anticancer Drug Discov 2012;7(1):118-31.
Nishida N, et al. Vasc Health Risk Manag 2006;2(3):213-9.
Papetti M, et al. Am J Physiol Cell Physiol 2002;282(5):C947-70.
Hanahan D, et al. Cell 2011;144(5):646-74.
Carmeliet P, et al. Nature 2011;473(7347):298-307.
Rashdan S, et al. Expert Opin Pharmacother 2014;15(5):729-39.
Hilberg F, et al. Cancer Res 2008;68(12):4774-82.
Ferrara N, et al. Nat Med 2003;9(6):669-76.
Andrae J, et al. Genes Dev 2008;22(10):1276-312.
Ahmad I, et al. Biochim Biophys Acta 2012;1823(4):850-60.
Hilberg F, et al. J Thorac Oncol 2007;2(8):S380.
Kutluk Cenik B, et al. Mol Cancer Ther 2013;12(6):992–1001.
Huang RY, et al. Oncotarget 2015;6(26):22098–113.
Reck M, et al. Lancet Oncol 2014;15(2):143–55.
ClinicalTrials.gov. NCT01907100. http://clinicaltrials.gov/ct2/show/NCT01907100. (Accessed: July 2017).
Cutsem EV, et al. Ann Oncol 2016;29(Suppl. 6):Abstract LBA20_PR.
du Bois A, et al. Lancet Oncol 2016;17(1):78–89.
Meyer T, et al. J Clin Oncol 2015;33(Suppl.):Abstract 4074.
Eisen T, et al. Br J Cancer 2015;113(8):1140–7.
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue